Allarity Therapeutics expands in-house lab to add proteomics, cell line research
Expansion adds proteomics and cell line research capabilities, broadens external services and is not expected to change cash runway.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Allarity Therapeutics, Inc. (ALLR) Adds Proteomics and Cell Line Capabilities
Allarity Therapeutics expanded its lab to include proteomics and cell line research to support stenoparib studies and external services, saying this will not affect its current cash runway.Material DetailsContext by AI AnalystThis is an incremental R&D and services expansion aligned with Allarity’s…